UMASS MEMORIAL MEDICAL CENTER NAMES NEW CHIEF OF HEMATOLOGY/ONCOLOGY
Alan G. Rosmarin, MD, will lead cancer care initiatives and promote clinical research growth as deputy director of the UMass Memorial Cancer Center

June 14, 2007

WORCESTER, Mass.—Alan G. Rosmarin, MD, has been named chief of the Division of Hematology/Oncology within the Department of Medicine at UMass Memorial Medical Center. In addition, Dr. Rosmarin will serve as deputy director of the UMass Memorial Cancer Center at the University of Massachusetts Medical School and UMass Memorial. Rosmarin joins UMass Memorial and the Medical School from the Warren Alpert Medical School of Brown University, where he was interim director of hematology, director of the hematology/oncology fellowship program and associate professor of medicine, molecular biology, cell biology and biochemistry.

“Dr. Rosmarin’s previous experience leading research and education initiatives at a prominent academic medical center makes him a superb choice for this position.  We look forward to supporting him as he applies that same expertise and dedication to leading the clinical operations of the division and the Cancer Center,” said Chair of Medicine Robert W. Finberg, MD, the Richard M. Haidack Professor of Medicine and professor of molecular genetics & microbiology.

“I'm very excited to be joining the UMass and UMass Memorial community,” said Dr. Rosmarin.  “I look forward to supporting the ongoing coupling of the remarkable scientific resources of UMass Medical School with the clinical strengths of UMass Memorial Health Care as we continue to provide extraordinary clinical and translational opportunities.” 

The Division of Hematology/Oncology provides expert diagnosis, treatment and support of cancer patients coupled with extensive research and clinical trials. The division strives to make available the latest advances from laboratories and research centers worldwide to ensure that UMass Memorial patients receive the most cutting-edge treatment modalities available through its Cancer Center of Excellence. In his capacity as division chief, Rosmarin will provide leadership and direction supported by a widely respected team of cancer specialists.  His responsibilities include planning, direction and evaluation of the delivery systems, standards and objectives.  “I look forward to applying my experience as a clinical and laboratory scientist, an educator, and a practicing physician to a place with such great promise for translating research into novel cancer treatments and excellent clinical care,” said Dr. Rosmarin.

The UMass Memorial Cancer Center, which is under the direction of Dario C. Altieri, MD, the Eleanor Eustis Farrington Chair in Cancer Research and Professor and Chair of Cancer Biology,   is an interdisciplinary and transdepartmental initiative that combines outstanding clinical care, cutting-edge research and wide-ranging preventive and behavioral studies to provide advanced cancer care to oncology patients. The center integrates some of the most vital cancer research and treatment activities available today with an intrinsic basic research component, focused on hematopoiesis, bone marrow stem cells and experimental transplantation. Cancer prevention and epidemiology are also prominent activities at the Cancer Center. As deputy director of the center, Rosmarin will work with investigators and staff to encourage innovative collaborations and actively promote the development of projects dedicated to bringing the work of the bench to the bedside.

 

“With Dr. Rosmarin’s enthusiastic and skilled leadership, we are poised to increase the amount of clinically related cancer research being conducted at UMMS,” said Dr. Altieri. “The work we are doing now to build the Cancer Center will help to make new kinds of therapies available to those afflicted with cancer. Dr. Rosmarin will no doubt contribute some of the vital leadership needed to reach this goal.”

“Dr. Rosmarin will be a particularly important addition to our efforts to accelerate clinical trials here at the Medical School,” said Terry R. Flotte, MD,  Dean of the School of Medicine. “His work will enhance our focus on translational research to the benefit of the patients of the region.”

A native of New York, Rosmarin received his undergraduate degree in biology from Vassar College, where he was elected to Phi Beta Kappa and awarded the Nourse Fellowship in Medicine. After receiving his medical degree from the University of Medicine and Dentistry of New Jersey-Rutgers Medical School in 1981, he completed his internship and residency in medicine and fellowship in hematology/oncology at Beth Israel Hospital/Harvard Medical School.

Rosmarin joined Brown Medical School in 1989. He was named interim director of hematology there in 1994 and director of the Hematology/Oncology Fellowship in 1998. In 2000, he was appointed director of the Brown University Oncology Group, and in 2002, director of the Lifespan Clinical Oncology Research.

Rosmarin’s primary research interest is the regulation of transcription in myeloid differentiation. Specifically, he studies the transcription factor, GABP, in the growth and maturation of white blood cells. Using molecular biology, biochemistry and unique animal models, his lab has demonstrated that GABP is essential for normal blood cell development and that it also plays key roles in such processes as cell growth and embryo formation.

Rosmarin is the author of more than 50 publications and abstracts and his research has been supported by the National Institutes of Health, American Cancer Society and Lifespan (Rhode Island Hospital). He is a member of a number of professional organizations, including the American Society of Hematology, the American Society of Microbiology, the American Federation for Clinical Research, the American Society of Clinical Oncology and the New England Cancer Society. In addition to serving on the editorial board of Stem Cells, Rosmarin has served as a reviewer for a number of prestigious journals, including Cancer, Developmental Biology, Experimental Hematology, Leukemia, Leukemia Research and Proceedings of the National Academy of Sciences.

###

About UMass Memorial Health Care

UMass Memorial Health Care is Central Massachusetts’ largest not-for-profit health care delivery system, covering the complete health care continuum with UMass Memorial Medical Center, its academic medical center, member and affiliated community hospitals, free-standing primary care practices, ambulatory outpatient clinics, a long-term care facility, home health agencies, hospice programs, a rehabilitation group and mental health services. UMass Memorial is the clinical partner of the University of Massachusetts Medical School. Visit http://www.umassmemorial.org for additional information.

About the University of Massachusetts Medical School

The University of Massachusetts Medical School, one of the fastest growing academic health centers in the country, has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research.  The Medical School attracts more than $176 million in research funding annually, 80 percent of which comes from federal funding sources. UMMS is the academic partner of UMass Memorial Health Care, the largest health care provider in Central Massachusetts. For more information visit www.umassmed.edu.

Contact: Alison Duffy, 508-856-2000